FS.10 The
scores for the generic QoL measures were similar.5
A British RCT, reported by Lattimer et al176 found that
physician-compounded UGFS was 3.15 times less expensive than EVLA (£230.24 vs £724.72) with comparable
effectiveness. However, 56% (vs 6%) of the patients who
had undergone UGFS had